{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T11:14:21Z","timestamp":1764587661431,"version":"3.46.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Umea University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Our aim was to explore clinical outcomes between patients with- and without of optimal medical therapy (OMT) in patients with reduced left ventricular ejection fraction (LVEF) undergoing coronary artery bypass graft surgery (CABG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-centre observational study, all patients who underwent isolated CABG with a preoperative LVEF of \u2264\u200940% between 2012 and 2021 were included. Individual data were collected from the medical health records and the register Carath. OMT was defined as prescription of renin-angiotensin-aldosterone system inhibitor (RAAS-I), beta-blocker (BB), Acetylsalicylic acid (ASA) and statins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      102 patients were identified. The frequency of patients with OMT was 44% at admission and 67% 72%, 69% and 68% at discharge, 2 months, 1 year and 2 years follow-up. Patients with OMT at discharge had a significant longer median time to the composite endpoint of first-time hospitalization and all-cause mortality compared to the No-OMT group (1.7 versus 7.1 years, log rank\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0038). OMT at discharge was associated with a lower adjusted risk of all-cause mortality and first-time hospitalization for heart failure (adjusted hazard ratio, 0.25; 95% confidence interval, 0.11\u20130.58; p\u2009=\u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The prescription rate of OMT increased until the 2 months follow-up with no further increases in dose at 1 year and 2 years follow-up. Patients undergoing CABG with a preoperative reduced left ventricular ejection fraction that were prescribed OMT at discharge had better outcomes in terms of a reduced risk of hospitalization for heart failure and all-cause mortality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-025-05384-2","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T07:05:16Z","timestamp":1764227116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimal medical therapy in patients with reduced left ejection fraction undergoing coronary artery bypass graft surgery"],"prefix":"10.1186","volume":"25","author":[{"given":"Anna Jonsson","family":"Holmdahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saman","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Birring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattias","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krister","family":"Lindmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"5384_CR1","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nrcardio.2016.25","volume":"13","author":"B Ziaeian","year":"2016","unstructured":"Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13:368\u201378.","journal-title":"Nat Rev Cardiol"},{"key":"5384_CR2","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1001\/jamacardio.2016.1465","volume":"1","author":"M Dal\u00e9n","year":"2016","unstructured":"Dal\u00e9n M, Lund LH, Ivert T, Holzmann MJ, Sartipy U. Survival after coronary artery bypass grafting in patients with preoperative heart failure and preserved vs reduced ejection fraction. JAMA Cardiol. 2016;1:530\u20138.","journal-title":"JAMA Cardiol"},{"key":"5384_CR3","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa1602001","volume":"374","author":"EJ Velazquez","year":"2016","unstructured":"Velazquez EJ, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med. 2016;374:1511\u201320.","journal-title":"N Engl J Med"},{"key":"5384_CR4","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1056\/NEJMoa1100356","volume":"364","author":"EJ Velazquez","year":"2011","unstructured":"Velazquez EJ, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364:1607\u201316.","journal-title":"N Engl J Med"},{"key":"5384_CR5","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.amjmed.2020.10.017","volume":"134","author":"R Crosier","year":"2021","unstructured":"Crosier R, et al. Intensity of Guideline-Directed medical therapy for coronary heart disease and ischemic heart failure outcomes. Am J Med. 2021;134:672\u2013e681674.","journal-title":"Am J Med"},{"key":"5384_CR6","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","volume":"400","author":"A Mebazaa","year":"2022","unstructured":"Mebazaa A, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400:1938\u201352.","journal-title":"Lancet"},{"key":"5384_CR7","doi-asserted-by":"publisher","first-page":"14909","DOI":"10.1038\/s41598-017-15004-5","volume":"7","author":"R Wurm","year":"2017","unstructured":"Wurm R, et al. Quality of medical therapy in heart failure patients undergoing elective revascularisation: a protective effect of disease modifying therapy at discharge. Sci Rep. 2017;7:14909.","journal-title":"Sci Rep"},{"key":"5384_CR8","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.athoracsur.2011.06.017","volume":"92","author":"KD Algarni","year":"2011","unstructured":"Algarni KD, Maganti M, Yau TM. Predictors of low cardiac output syndrome after isolated coronary artery bypass surgery: trends over 20 years. Ann Thorac Surg. 2011;92:1678\u201384.","journal-title":"Ann Thorac Surg"},{"key":"5384_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ijcard.2018.09.092","volume":"274","author":"D Hertzberg","year":"2019","unstructured":"Hertzberg D, et al. Heart failure and the risk of acute kidney injury in relation to ejection fraction in patients undergoing coronary artery bypass grafting. Int J Cardiol. 2019;274:66\u201370.","journal-title":"Int J Cardiol"},{"key":"5384_CR10","doi-asserted-by":"crossref","unstructured":"McDonagh TA et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42(36):3599\u2013726.","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"5384_CR11","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3109\/00365513.2011.557086","volume":"71","author":"J Bjork","year":"2011","unstructured":"Bjork J, Grubb A, Sterner G, Nyman U. Revised equations for estimating glomerular filtration rate based on the Lund-Malmo study cohort. Scand J Clin Lab Invest. 2011;71:232\u20139.","journal-title":"Scand J Clin Lab Invest"},{"key":"5384_CR12","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1093\/eurheartj\/ehz714","volume":"41","author":"E Bj\u00f6rklund","year":"2020","unstructured":"Bj\u00f6rklund E, et al. Secondary prevention medications after coronary artery bypass grafting and long-term survival: a population-based longitudinal study from the SWEDEHEART registry. Eur Heart J. 2020;41:1653\u201361.","journal-title":"Eur Heart J"},{"key":"5384_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jchf.2017.09.015","volume":"6","author":"MC Bahit","year":"2018","unstructured":"Bahit MC, Kochar A, Granger CB. Post-myocardial infarction heart failure. JACC Heart Fail. 2018;6:179\u201386.","journal-title":"JACC Heart Fail"},{"key":"5384_CR14","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","volume":"357","author":"HJ Dargie","year":"2001","unstructured":"Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385\u201390.","journal-title":"Lancet"},{"key":"5384_CR15","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1056\/NEJM199209033271001","volume":"327","author":"MA Pfeffer","year":"1992","unstructured":"Pfeffer MA, et al. Effect of Captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med. 1992;327:669\u201377.","journal-title":"N Engl J Med"},{"key":"5384_CR16","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309\u201321.","journal-title":"N Engl J Med"},{"key":"5384_CR17","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/CIRCULATIONAHA.114.013042","volume":"131","author":"J Iqbal","year":"2015","unstructured":"Iqbal J, et al. Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting: insights from the synergy between percutaneous coronary intervention with TAXUS and cardiac surgery (SYNTAX) trial at the 5-year follow-up. Circulation. 2015;131:1269\u201377.","journal-title":"Circulation"},{"key":"5384_CR18","doi-asserted-by":"crossref","unstructured":"Farsky PS et al. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy. J Thorac Cardiovasc Surg2022;164(6):1890\u20139 .","DOI":"10.1016\/j.jtcvs.2020.12.094"},{"key":"5384_CR19","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1161\/CIR.0000000000000182","volume":"131","author":"A Kulik","year":"2015","unstructured":"Kulik A, et al. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. Circulation. 2015;131:927\u201364.","journal-title":"Circulation"},{"key":"5384_CR20","doi-asserted-by":"crossref","unstructured":"Sousa-Uva M et al. 2017 EACTS Guidelines on perioperative medication in adult cardiac surgery. Eur J Cardiothorac Surg. 2018;53(1):5\u201333.","DOI":"10.1093\/ejcts\/ezx314"},{"key":"5384_CR21","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024703","volume":"11","author":"A Taha","year":"2022","unstructured":"Taha A, et al. Stroke risk stratification in patients with postoperative atrial fibrillation after coronary artery bypass grafting. J Am Heart Assoc. 2022;11:e024703.","journal-title":"J Am Heart Assoc"},{"key":"5384_CR22","first-page":"28","volume":"9","author":"PK Srivastava","year":"2021","unstructured":"Srivastava PK, et al. Heart failure hospitalization and guideline-directed prescribing patterns among heart failure with reduced ejection fraction patients. JACC: Heart Failure. 2021;9:28\u201338.","journal-title":"JACC: Heart Failure"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05384-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-05384-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05384-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T11:05:39Z","timestamp":1764587139000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-05384-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5384"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-05384-2","relation":{},"ISSN":["1471-2261"],"issn-type":[{"type":"electronic","value":"1471-2261"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complies with the Declaration of Helsinki. Swedish Ethical Review Authority has approved the study (registration number 2022-02575-01). The Ethics Committee waived the need for individual patient consent as this was a retrospective observational study without any intervention.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"855"}}